7 STRAITS VIEW, SINGAPORE, U0
Earnings Release
Wave Life Sciences Ltd. Shareholders Approve Redomiciliation Proposal
Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces Hearing on Proposed Redomiciliation to the United States
Announces Proposed Redomiciliation to the United States
Wave Life Sciences Reports Positive Phase 1 INLIGHT Data: Body Composition and Fat Reductions
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q2
Amended Annual Report
Q1
FY 2024
Q3
Effectiveness Notice
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
PRER14A
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
S-8 POS